



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/541,073	06/29/2005	Yoshiyuki Ishikura	47237-0561-00 (216942)	4059
55694	7590	06/03/2009	EXAMINER	
DRINKER BIDDLE & REATH (DC)				PURDY, KYLE A
1500 K STREET, N.W.		ART UNIT		PAPER NUMBER
SUITE 1100		1611		
WASHINGTON, DC 20005-1209				
		MAIL DATE		DELIVERY MODE
		06/03/2009		PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief	Application No.	Applicant(s)
	10/541,073	ISHIKURA ET AL.
	Examiner	Art Unit
	Kyle Purdy	1611

--The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

THE REPLY FILED 26 May 2009 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.

1. The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods:

a) The period for reply expires 3+3 months from the mailing date of the final rejection.

b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.

Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).

Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

NOTICE OF APPEAL

2. The Notice of Appeal was filed on 26 May 2009. A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a).

AMENDMENTS

3. The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will not be entered because

(a) They raise new issues that would require further consideration and/or search (see NOTE below);

(b) They raise the issue of new matter (see NOTE below);

(c) They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or

(d) They present additional claims without canceling a corresponding number of finally rejected claims.

NOTE: _____. (See 37 CFR 1.116 and 41.33(a)).

4. The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324).

5. Applicant's reply has overcome the following rejection(s): _____.

6. Newly proposed or amended claim(s) _____ would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).

7. For purposes of appeal, the proposed amendment(s): a) will not be entered, or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.

The status of the claim(s) is (or will be) as follows:

Claim(s) allowed: _____.

Claim(s) objected to: _____.

Claim(s) rejected: 3-6 and 29-33.

Claim(s) withdrawn from consideration: _____.

AFFIDAVIT OR OTHER EVIDENCE

8. The affidavit or other evidence filed after a final action, but before or on the date of filing a Notice of Appeal will not be entered because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is necessary and was not earlier presented. See 37 CFR 1.116(e).

9. The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will not be entered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant fails to provide a showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1).

10. The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached.

REQUEST FOR RECONSIDERATION/OTHER

11. The request for reconsideration has been considered but does NOT place the application in condition for allowance because:
See Continuation Sheet.

12. Note the attached Information Disclosure Statement(s). (PTO/SB/08) Paper No(s). _____.

13. Other: _____.

/Kyle Purdy/
Examiner, Art Unit 1611
June 2, 2009

/David J Blanchard/
Primary Examiner, Art Unit 1643

Continuation of 11. does NOT place the application in condition for allowance because: Applicants arguments filed 05/26/2009 regarding the rejection of claims 4 and 29 made by the Examiner under 35 USC 102(e) over Akimoto et al. (US 2004/0266874) have been fully considered but they are not found persuasive.

In regards to the 102(e) rejection, Applicant asserts the following:

A) The mechanism of action of the present invention and of Akimoto differ, therefore anticipation does not exist.

In response to A, something which is old does not become patentable upon the discovery of a new property. See MPEP 2112. The claiming of a new use, new function or unknown property which is inherently present in the prior art does not necessarily make the claim patentable. The fact that Applicant is identifying a method of administering arachidonic acid as being capable of improving blood vessel elasticity does not impart patentable weight because the claimed active step is already known in the art. And utilization of that step would necessarily improve blood vessel elasticity in aging individuals, which includes any possible person. Applicants arguments are not found persuasive.

Applicants arguments filed 05/26/2009 regarding the rejection of claims 3-6 and 29-32 made by the Examiner under 35 USC 103(a) over Akimoto, evidenced by Strub (Southern Medical Journal) and Nucleus Medical have been fully considered but they are not found persuasive.

In regards to the 103(a) rejection, Applicant asserts the following:

B) The rejection should be withdrawn because the reference of Akimoto falls under 103(c) due to Akimoto and the present invention being commonly owned.

In response to B, this argument is not found persuasive. 103(c) would be sufficient to overcome the reference of Akimoto if both of the priority documents (JP 2003-369147 and PCT/JP05/16351) were provided in English. Applicant cannot rely upon the foreign priority papers to overcome this rejection because a translation of said papers has not been made of record in accordance with 37 CFR 1.55. See MPEP 201.15. Applicants argument is not found persuasive..